0.5357
price up icon4.36%   0.0224
 
loading

Perché le azioni Optinose Inc (OPTN) sono in ribasso?

Abbiamo notato un calo di 5.53% nelle azioni di Optinose Inc (OPTN) durante la sessione di negoziazione di 2024-11-26. Sebbene ciò possa essere attribuito alla normale volatilità o a vari fattori interni ed esterni, tieni presente che stiamo monitorando attivamente la situazione e forniremo aggiornamenti tempestivi il prima possibile!
2023-12-06:

Shares of OptiNose Inc (OPTN) dropped by 16.33% from $1.47 to $1.23 in the trading on Wednesday, December 6, 2023. The reason why OPTN is down today is due to the announcement that the U.S. Food and Drug Administration (FDA) has extended the review period for the company's supplemental new drug application (sNDA) requesting approval of XHANCE as a treatment for chronic rhinosinusitis. The new Prescription Drug User Fee Act (PDUFA) goal date for the review is March 16, 2024. The FDA's decision to extend the review period for XHANCE's sNDA has raised uncertainties and delayed potential approval. This extension likely led to concerns among investors, resulting in the notable drop in the stock price.

$90.27
price up icon 0.83%
$13.13
price up icon 0.00%
$86.59
price up icon 0.19%
$61.00
price up icon 0.41%
$126.59
price down icon 1.03%
$13.22
price up icon 1.07%
Capitalizzazione:     |  Volume (24 ore):